 Within Histogen's proprietary bioreactors, newborn fibroblasts are seeded onto a beadlike structure and conditioned with liquid media. Within a few days cells have produced a dense embryonic-like ExceltrixTM and have secreted wnt proteins and various growth factors into the liquid that bathes them. |
|
|
|
| View the bioreactors in | |
 action |
|
Our Technology
Through Histogen's proprietary technology process that mimics the embryonic environment, including very low oxygen and low gravity conditions, newborn cells develop stem cell markers and become embryonic-like and naturally produce vital proteins and growth factors which are characteristic of young, rapidly developing tissue.
From this process, Histogen extracts two products - an insoluble human extracellular matrix (hECM) and a soluble complex of proteins - with a variety of applications in various markets and segments of the life science industry.
Histogen's one technology, two products, numerous applications model offers a continuum of product introduction opportunities, from lead applications such as hair regrowth and skincare to longer timeline therapeutic applications including oncology and wound care.
- Fibroblasts are easy to obtain and grow
- There are no ethical drawbacks to the use and commercialization of fibroblasts
- Histogen has successfully developed commercial-scale production processes which are economically viable
- All of the derivatives of the fibroblast conditioning process can be used, creating a spectrum of products for a variety of markets from one core technology
© Histogen Inc., CA 92101